Clinical improvement of pemphigus-like mucocutaneous disease in a patient with CLL following initiation of zanubrutinib: a case report. (PubMed, Front Immunol) - Oct 1, 2026 - "Current management of PNP primarily involves glucocorticoids, immunosuppressants, and rituximab. If zanubrutinib did play a role, the mechanism might involve enhanced disease control or immune modulation. However, the current evidence is insufficient to draw a firm conclusion, and its true efficacy needs to be evaluated in further studies."
Journal • Chronic Lymphocytic Leukemia • Dermatology • Hematological Malignancies • Immune Modulation • Immunology • Leukemia • Mucositis • Oncology • Pain • Pemphigus Vulgaris • Stomatitis
|
|
Chengbin Lu; Dongjie Sun; Tianyu Li; Tong Kang; Ying Tu
|